首页> 美国卫生研究院文献>British Journal of Clinical Pharmacology >Effect of UGT1A1 UGT1A3 DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer

【2h】

Effect of UGT1A1 UGT1A3 DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer

机译：UGT1A1UGT1A3DIO1和DIO2多态性对分化型甲状腺癌患者抑制TSH所需的L-甲状腺素剂量的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimTo evaluate the impact of genetic polymorphisms in uridine 5′-glucuronosylytansferases UGT1A1 and UGT1A3 and iodothyronine-deiodinases types 1 and 2 on levothyroxine (T4; 3,5,3′,5′-triiodo-L-thyronine) dose requirement for suppression of thyrotropin (TSH) secretion in patients with differentiated thyroid cancer (DTC).

机译：目的评估尿苷5'-葡萄糖醛酸糖基转移酶UGT1A1和UGT1A3以及1和2型碘甲状腺素-脱碘酶的遗传多态性对抑制甲状腺素（T4; 3,5,3'，5'-三碘代-L-甲状腺素）剂量的影响分化型甲状腺癌（DTC）患者的促甲状腺激素（TSH）分泌。

著录项

期刊名称 British Journal of Clinical Pharmacology
作者
Ana B Santoro; Daniela D Vargens; Mateus de Camargo Barros Filho; Daniel A Bulzico; Luiz Paulo Kowalski; Ricardo M R Meirelles; Daniela P Paula; Ronaldo R S Neves; Cencita N Pessoa; Claudio J Struchine; Guilherme Suarez-Kurtz;
展开▼
作者单位

展开▼
年(卷),期 2014(78),5
年度 2014
页码 1067–1075
总页数 9
原文格式 PDF
正文语种
中图分类药学;
关键词
Brazilian population differentiated thyroid cancer iodothyronine-deiodinases L-thyroxine pharmacogenomics uridine glucuronyltransferases;

机译：巴西人口;分化型甲状腺癌;碘甲状腺素-脱碘酶;L-甲状腺素;药物基因组学;尿苷葡糖醛酸转移酶;

相似文献

外文文献
中文文献
专利

1. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer [J] . Santoro Ana B., Vargens Daniela D., Barros Filho Mateus de Camargo, British Journal of Clinical Pharmacology . 2014,第5期

机译：UGT1A1，UGT1A3，DIO1和DIO2多态性对分化型甲状腺癌患者抑制TSH所需的L-甲状腺素剂量的影响
2. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L‐thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer [J] . Santoro Ana B., Vargens Daniela D., Barros Filho Mateus de Camargo, British journal of clinical pharmacology . 2014,第5期

机译：UGT1A1，UGT1A3，DIO1和DIO2多态性对分化型甲状腺癌患者抑制TSH所需的L-甲状腺素剂量的影响
3. L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer: Effect of a novel UGT1 marker, rs11563250A > G [J] . Santoro Ana Beatriz, Struchiner Claudio Jose, Suarez-Kurtz Guilherme British Journal of Clinical Pharmacology . 2016,第5期

机译：分化型甲状腺癌患者抑制TSH所需的L-甲状腺素剂量：新型UGT1标记rs11563250A> G的作用
4. Calculation of accumulated absorbed radiation dose in patients with differentiated thyroid cancer [C] . Erika Allauca, Vilma Yanchapanta, Javier Toasa Tapia International Congress on Physics ESPOCH . 2018

机译：分化甲状腺癌患者累积吸收辐射剂量的计算
5. L‐thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer: Effect of a novel UGT1 marker rs11563250A G [O] . Ana Beatriz Santoro, Claudio José Struchiner, Guilherme Suarez‐Kurtz 2016

机译：分化型甲状腺癌患者抑制TSH所需的L-甲状腺素剂量：新型UGT1标记rs11563250A G的作用
6. L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer: Effect of a novel UGT1 marker, rs11563250A > G [O] . Ana Beatriz Santoro, Claudio José Struchiner, Guilherme Suarez-Kurtz 2016

机译：分化甲状腺癌患者的TSH抑制所需的L-甲状腺素剂量：新型UGT1标记的作用，RS11563250A> G.

相关主题

Effect of UGT1A1 UGT1A3 DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer

摘要

著录项

相似文献

相关主题

期刊订阅